Office for RESEARCH
NIH Award from the National Institute of Allergy and Infectious Diseases
Principal investigator: Greg A. Smith, microbiology-immunology,
Feinberg School of Medicine
• Project: Alpha-Herpesvirus Assembly, Egress and Viral Particle Heterogeneity
• Start Date: September 1, 2009
• Total Award Amount: $303,761
How the results of this project will benefit society:
Neuroinvasive herpesviruses are the causative agents of a number of severe diseases including shingles, encephalitis, neonatal infections and herpes keratitis (the leading cause of infectious blindness in America). This proposal focuses on understanding the molecular mechanisms that underlie the posal is based on the hypothesis that herpesvirus assembly assembly and egress of herpesvirus particles, with the long- and egress are coupled processes that occur through a series term goal of identifying new targets for the intervention of of sequential steps both in the nucleus and cytoplasm of infected cells, and that each of these steps are effected in part by the VP1/2 protein. Our goal is to refine our understanding The problem the project is trying to solve:
of these steps at the level of the protein interactions that con- The neuroinvasive herpesviruses are a highly-prevalent group tribute to the dynamics of viral egress. This proposal includes of the alpha-herpesvirus subfamily that includes the human comparative studies of model viruses from the two neuroin- pathogens: herpes simplex virus types 1 and 2 (HSV–1, HSV-2), vasive herpesviruses groups, the simplexviruses (represented and varicella zoster virus (VZV). An additional member of this by HSV-1) and the varicelloviruses (represented by PRV), to group is a virus of veterinary significance, pseudorabies virus develop a comprehensive analysis of the properties of these (PRV), which historical y has provided models for studying viral pathogenesis. Despite the availability of the antiviral compound acyclovir, several severe forms of disease caused This award is funded under the American Recovery and Re- by these viruses remain prevalent in this country and world investment Act of 2009, NIH Award number: 1R56AI080658- wide. Infections associated with high rates of morbidity or mortality include encephalitis, keratitis, shingles and dissemi- nated infections in newborns. Novel strategies to interfere with the assembly and egress of these viruses could prove valuable to treatment of infections, yet much of the herpesvi-
How this project will work:
In this application we leverage our expertise in infectious clone mutagenesis and single viral particle fluorescence imaging methods to dissect viral structural composition in living-cells and extracellularly, and to address the molecular pathways guiding viral assembly and egress. New evidence is provided indicating that the very large herpesvirus tegument protein, VP1/2, is a key effector of viral assembly. This pro-


Xpp-pdf support utility

Pharmaceutical Law & Industry Report® Reproduced with permission from Pharmaceutical Law & Industry Report, 11 PLIR , 9/20/13. Copyright ஽ 2013 byThe Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.comInterpreting Actavis , Young said that even though thegeneric defendants in the Nexium case did not receivePlaintiffs’ Antitrust Claims May Proceedany kind of dir

Chelsea Therapeutics Granted MHRA Approval to Begin Phase II Trial of Droxidopa in Fibromyalgia Company Anticipates Dosing First Patient in Late September CHARLOTTE, N.C., July 23, 2008 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase II trial of Droxidopa,

Copyright © 2011-2018 Health Abstracts